MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1594-1604

  Ben Hamo, Rotem ^a   Efroni, Sol ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Cancer; microRNA; Phenotype; Regulation; Signaling pathways

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA; MICRORNA 181A 1; MICRORNA 193B; MICRORNA 199A 2; MICRORNA 203; MICRORNA 214; MICRORNA 221; MICRORNA 30E; MICRORNA 324; MICRORNA 375; MICRORNA 532; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CUTANEOUS MELANOMA; GENE EXPRESSION; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MATHEMATICAL MODEL; MEASUREMENT ACCURACY; NEOPLASM; OVARY ADENOCARCINOMA; PHENOTYPE; PREDICTION; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; APOPTOSIS; GENETICS; HUMAN; PATHOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; HUMANS; MICRORNAS; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84922732621     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2734     Document Type: Article

References (58)

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006; 6:857-866.
2. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature reviews Cancer. 2011; 11:644-656.
3. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007; 120:1833-1840.
4. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature reviews Genetics. 2009; 10:704-714.
5. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007; 282:1479-1486.
6. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102:13944-13949.
7. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64:3753-3756.
8. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature reviews Cancer. 2011; 11:849-864.
9. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007; 26:2799-2803.
10. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature cell biology. 2009; 11:228-234.
11. Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2011; 47:163-174.
12. Fu LL, Wen X, Bao JK, Liu B. MicroRNA-modulated autophagic signaling networks in cancer. The international journal of biochemistry & cell biology. 2012; 44:733-736.
13. Lu TX, Hartner J, Lim EJ, Fabry V, Mingler MK, Cole ET, Orkin SH, Aronow BJ, Rothenberg ME. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol. 2011; 187:3362-3373.
14. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012; 55:1852-1862.
15. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer research. 2008; 68:3566-3572.
16. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Molecular and cellular biology. 2009; 29:5923-5940.
17. Glass C, Singla DK. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. American journal of physiology Heart and circulatory physiology. 2011; 301:H2038-2049.
18. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nature medicine. 2011; 17:64-70.
19. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. PID: the Pathway Interaction Database. Nucleic acids research. (Database issue). 2009; 37:D674-679.
20. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. Journal of biomedical informatics. 2011; 44:839-847.
21. Storey JD. A direct approach to false discovery rates. J Roy Stat Soc B. 2002; 64:479-498.
22. Efroni S, Schaefer CF, Buetow KH. Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PloS one. 2007; 2:e425.
23. Ben-Hamo R, Efroni S. Correction: Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome medicine. 2012; 4:87.
24. Ben-Hamo Rotem ES. Network as biomarker: Quantifying transcriptional co-expression to stratify cancer clinical phenotypes. Systems Biomedicine. 2013; 1.
25. Greenblum SI, Efroni S, Schaefer CF, Buetow KH. The PathOlogist: an automated tool for pathway-centric analysis. BMC bioinformatics. 2011; 12:133.
26. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer research. 2001; 61:5979-5984.
27. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM. Effects of estrogen on global gene expression: Identification of novel targets of estrogen action. Cancer research. 2000; 60:5977-5983.
28. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005; 19:833-842.
29. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP, Huang TH. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer research. 2004; 64:8184-8192.
30. Osborne CK. Steroid hormone receptors in breast cancer management. Breast cancer research and treatment. 1998; 51:227-238.
31. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995; 10:2435-2446.
32. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochemical and biophysical research communications. 2010; 396:63-66.
33. Ben-Hamo R, Efroni S. Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC systems biology. 2012; 6.
34. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature cell biology. 2007; 9:201-209.
35. Tominaga N, Naoi Y, Shimazu K, Nakayama T, Maruyama N, Shimomura A, Kim SJ, Tamaki Y, Noguchi S. Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23:3051-3057.
36. Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. International Journal of Cancer. 1999; 84:122-128.
37. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:1608-1613.
38. Ma F, Liu X, Li D, Wang P, Li N, Lu L, Cao X. MicroRNA-466l upregulates IL-10 expression in TLRtriggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation. J Immunol. 2010; 184:6053-6059.
39. Tanaka H, Sasayama T, Tanaka K, Nakamizo S, Nishihara M, Mizukawa K, Kohta M, Koyama J, Miyake S, Taniguchi M, Hosoda K, Kohmura E. MicroRNA-183 upregulates HIF-1alpha by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. Journal of neuro-oncology. 2013; 111:273-283.
40. Ye W, Qin F, Zhang J, Luo R, Chen HF. Atomistic mechanism of microRNA translation upregulation via molecular dynamics simulations. PloS one. 2012; 7:e43788.
41. Guo AY, Sun J, Jia P, Zhao Z. A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC systems biology. 2010; 4:10.
42. Yuan X, Liu C, Yang P, He S, Liao Q, Kang S, Zhao Y. Clustered microRNAs' coordination in regulating proteinprotein interaction network. BMC systems biology. 2009; 3:65.
43. Xu J, Wong C. A computational screen for mouse signaling pathways targeted by microRNA clusters. RNA. 2008; 14:1276-1283.
44. Ulitsky I, Laurent LC, Shamir R. Towards computational prediction of microRNA function and activity. Nucleic acids research. 2010; 38:e160.
45. Qiu C, Wang J, Cui Q. miR2Gene: pattern discovery of single gene, multiple genes, and pathways by enrichment analysis of their microRNA regulators. BMC systems biology. 2011; 5Suppl 2:S9.
46. Nam S, Kim B, Shin S, Lee S. miRGator: an integrated system for functional annotation of microRNAs. Nucleic acids research. 2008; 36:D159-164.
47. Green JE, Desai K, Ye Y, Kavanaugh C, Calvo A, Huh JI. Genomic approaches to understanding mammary tumor progression in transgenic mice and responses to therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:385S-390S.
48. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. microRNAassociated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer research. 2011; 71:5635-5645.
49. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Ronneberg JA, Johnsen H, Navon R, Rodland E, Makela R, Naume B, Perala M, Kallioniemi O, Kristensen VN, Yakhini Z, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PloS one. 2011; 6:e16915.
50. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A. A combined computational-experimental approach predicts human microRNA targets. Genes & development. 2004; 18:1165-1178.
51. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS biology. 2004; 2:e363.
52. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA. 2008; 14:1012-1017.
53. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nature genetics. 2005; 37:495-500.
54. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nature genetics. 2007; 39:1278-1284.
55. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004; 10:1507-1517.
56. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003; 115:787-798.
57. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD, Ideker T. A travel guide to Cytoscape plugins. Nature methods. 2012; 9:1069-1076.
58. Bastian M HS, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. International AAAI Conference on Weblogs and Social Media. 2009.